Sepsis is a potentially deadly condition that occurs when the immune system detects and responds to a new pathogen in the bloodstream, triggering a chain reaction of auto-immune damage. Worldwide, sepsis affects approximately 27 million people each year, up to 30% of mortality rate. Sepsis often occurs as a co-morbidity in patients with other serious conditions; it is especially problematic in older or infirm adults. The cost of Sepsis worldwide is estimated at €32 billion/year.
The timing of the diagnosis and treatments are key to controlling the disease – the earlier Sepsis is confirmed, the greater chance for patient survival and recovery. Current detection methods to confirm Sepsis take between 6 hours and two days. Methodology ranges from the use of serum biomarkers (results come in 6-12 hours), to testing for the pathogen (results come in 1-2 days).
A novel first-in-class in vitro cellular immunoassay that identifies sepsis after the first-hour of bloodstream infection.
We have developed a patented method and kit (with disposable) to identify immune activity biomarkers, that is 3x more sensitive than the current biomarker competitor (PCT) and provides a 10x faster diagnosis than pathogen identification.
Our biomarker appears after the first hour of infection, long before PCT can detect the presence of Sepsis. This will allow healthcare professionals to begin accurate treatment earlier – reducing the severity of the disease and decreasing the number of antibiotics or other drugs necessary for treatment.
Invitro disposable device: Lateral flow strip + Reactives
Reader device: simplifies the process
Funding and collaborators
The first rapid test that identifies bacteria in blood before they progress in
sepsis: Development and clinical validation of a device to identify cases of sepsis
through totally innovative technology and biomarkers that allow
the identification of the presence of sepsis, in very early stages of the
disease and in a much faster way than current methods.
Line of R&D projects in SMEs: 04/18/SO/0017.